Daniel Hayes

Summary

Affiliation: University of Michigan
Country: USA

Publications

  1. doi request reprint Molecular testing in breast cancer
    Costanza Paoletti
    Breast Oncology Program of the Comprehensive Cancer Center, and the Department of Internal Medicine, University of Michigan Health and Hospital System, Ann Arbor, Michigan 48109 email
    Annu Rev Med 65:95-110. 2014
  2. ncbi request reprint From genome to bedside: are we lost in translation?
    Daniel F Hayes
    University of Michigan Comprehensive Cancer Center, 1500 E Medical Center Drive, Ann Arbor, MI 48109, USA Electronic address
    Breast 22:S22-6. 2013
  3. pmc OMICS-based personalized oncology: if it is worth doing, it is worth doing well!
    Daniel F Hayes
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, 6312 Cancer Center, 1500 E, Medical Center Drive, Ann Arbor, MI 48109 0942, USA
    BMC Med 11:221. 2013
  4. ncbi request reprint Breaking a vicious cycle
    Daniel F Hayes
    University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109, USA
    Sci Transl Med 5:196cm6. 2013
  5. ncbi request reprint Circulating tumour cells: insights into tumour heterogeneity
    D F Hayes
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109, USA
    J Intern Med 274:137-43. 2013
  6. pmc Considerations in the development of circulating tumor cell technology for clinical use
    David R Parkinson
    New Enterprise Associates, Menlo Park, CA 94025, USA
    J Transl Med 10:138. 2012
  7. pmc CYP2D6 genotype and tamoxifen response
    James M Rae
    Breast Cancer Res 7:E6. 2005
  8. ncbi request reprint Is there a role for circulating tumor cells in the management of breast cancer?
    Daniel F Hayes
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Michigan, USA
    Clin Cancer Res 14:3646-50. 2008
  9. ncbi request reprint HER2 and response to paclitaxel in node-positive breast cancer
    Daniel F Hayes
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor 48109, USA
    N Engl J Med 357:1496-506. 2007
  10. ncbi request reprint Angiogenesis as targeted breast cancer therapy
    Daniel F Hayes
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, 6312 CCGC, Ann Arbor, MI 48109, USA
    Breast 16:S17-9. 2007

Collaborators

Detail Information

Publications92

  1. doi request reprint Molecular testing in breast cancer
    Costanza Paoletti
    Breast Oncology Program of the Comprehensive Cancer Center, and the Department of Internal Medicine, University of Michigan Health and Hospital System, Ann Arbor, Michigan 48109 email
    Annu Rev Med 65:95-110. 2014
    ..Further research is needed to enhance the number of tumor biomarker tests so that patients with breast cancer can get the correct treatment at the appropriate time. ..
  2. ncbi request reprint From genome to bedside: are we lost in translation?
    Daniel F Hayes
    University of Michigan Comprehensive Cancer Center, 1500 E Medical Center Drive, Ann Arbor, MI 48109, USA Electronic address
    Breast 22:S22-6. 2013
    ..A "Bad Tumor Marker Is as Bad as a Bad Drug". ..
  3. pmc OMICS-based personalized oncology: if it is worth doing, it is worth doing well!
    Daniel F Hayes
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, 6312 Cancer Center, 1500 E, Medical Center Drive, Ann Arbor, MI 48109 0942, USA
    BMC Med 11:221. 2013
    ..Please see related article: http://www.biomedcentral.com/1741-7015/11/220...
  4. ncbi request reprint Breaking a vicious cycle
    Daniel F Hayes
    University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109, USA
    Sci Transl Med 5:196cm6. 2013
    ....
  5. ncbi request reprint Circulating tumour cells: insights into tumour heterogeneity
    D F Hayes
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109, USA
    J Intern Med 274:137-43. 2013
    ..Future studies are designed to determine the clinical utility of these novel technologies in either research or routine clinical settings. ..
  6. pmc Considerations in the development of circulating tumor cell technology for clinical use
    David R Parkinson
    New Enterprise Associates, Menlo Park, CA 94025, USA
    J Transl Med 10:138. 2012
    ....
  7. pmc CYP2D6 genotype and tamoxifen response
    James M Rae
    Breast Cancer Res 7:E6. 2005
  8. ncbi request reprint Is there a role for circulating tumor cells in the management of breast cancer?
    Daniel F Hayes
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Michigan, USA
    Clin Cancer Res 14:3646-50. 2008
    ..Recent technical advances offer the promise of further genotyping and phenotyping for important tumor-associated genes and proteins...
  9. ncbi request reprint HER2 and response to paclitaxel in node-positive breast cancer
    Daniel F Hayes
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor 48109, USA
    N Engl J Med 357:1496-506. 2007
    ..We hypothesized that HER2 positivity predicts a benefit from adjuvant doxorubicin doses above standard levels, from the addition of paclitaxel after adjuvant chemotherapy with doxorubicin plus cyclophosphamide, or from both...
  10. ncbi request reprint Angiogenesis as targeted breast cancer therapy
    Daniel F Hayes
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, 6312 CCGC, Ann Arbor, MI 48109, USA
    Breast 16:S17-9. 2007
    ..Small molecular inhibitors of VEGF receptor tyrosine kinase activity, such as sunitinib, appear promising. Nearly 40 years after it was first proposed, inhibition of angiogenesis appears to be gaining a role in medical oncology...
  11. ncbi request reprint Prognostic factors in breast cancer: current and new predictors of metastasis
    D F Hayes
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor 48109 0942, USA
    J Mammary Gland Biol Neoplasia 6:375-92. 2001
    ..This paper provides an overview of issues that need to be considered when analyzing studies of prognostic factors as well as a review of the currently recognized and the newer candidate prognostic factors...
  12. ncbi request reprint Markers of increased risk for failure of adjuvant therapies
    Daniel F Hayes
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Department of Medicine, University of Michigan Health System, 1500 E Medical Center Drive, Ann Arbor, MI 48109, USA
    Breast 12:543-9. 2003
    ....
  13. ncbi request reprint Clinical practice. Follow-up of patients with early breast cancer
    Daniel F Hayes
    University of Michigan Comprehensive Cancer Center, Ann Arbor 48109, USA
    N Engl J Med 356:2505-13. 2007
  14. ncbi request reprint Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival
    Daniel F Hayes
    Department of Internal Medicine and the Comprehensive Cancer Center, University of Michigan Health and Hospital System, Ann Arbor, Michigan 48109, USA
    Clin Cancer Res 12:4218-24. 2006
    ..In this study, additional follow-up data and CTC levels at subsequent follow-up visits were evaluated...
  15. ncbi request reprint Prognostic and predictive factors revisited
    Daniel F Hayes
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, CCGC 6312, 1500 E Medical Center Drive, Ann Arbor, MI 48109, USA
    Breast 14:493-9. 2005
    ..In particular, available data are often confounded by patient selection and the effects of systemic therapy, which are often not determined prospectively, not included in analyses, and not reported adequately...
  16. doi request reprint Is there a standard type and duration of adjuvant chemotherapy for early stage breast cancer?
    Daniel F Hayes
    University of Michigan Comprehensive Cancer Center, 1500 E Medical Center Drive, Ann Arbor, MI 48109, USA
    Breast 18:S131-4. 2009
    ..Thus, at this time there is no single standard type or duration of adjuvant chemotherapy, and physicians should choose from regimens that have proven benefit as demonstrated in randomized Phase III trials...
  17. ncbi request reprint Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer
    N Lynn Henry
    Department of Internal Medicine, Breast Oncology Program, University of Michigan Comprehensive Cancer Center, 1500 East Medical Center Drive, Ann Arbor, Michigan 48109, USA
    Oncologist 11:541-52. 2006
    ..Finally, new tumor marker reporting recommendations are discussed, the adoption of which may lead to improved design and publication of tumor marker studies in the future...
  18. ncbi request reprint Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662
    D F Hayes
    Georgetown University Medical Center, Washington, DC 20007, USA
    Clin Cancer Res 7:2703-11. 2001
    ....
  19. doi request reprint Disease related indicators for a proper choice of adjuvant treatments
    Daniel F Hayes
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109 5942, USA
    Breast 20:S162-4. 2011
    ..More recently, multi-parameter assays have become incorporated into prognostic calculations, principally in patients who are ER positive. None has been established to have clinical utility in patients who are ER negative...
  20. pmc Estrogen receptor genotypes, menopausal status, and the effects of tamoxifen on lipid levels: revised and updated results
    D F Hayes
    Department of Internal Medicine and Breast Oncology Program, Comprehensive Cancer Center, University of Michigan Health and Hospitals System, Ann Arbor, Michigan, USA
    Clin Pharmacol Ther 88:626-9. 2010
    ....
  21. pmc Estrogen receptor genotypes, menopausal status, and the lipid effects of tamoxifen
    N I Ntukidem
    Department of Medicine, Indiana University, Indianapolis, Indiana, USA
    Clin Pharmacol Ther 83:702-10. 2008
    ..002; gene-dose effect) and high-density lipoprotein (P=0.004; gene-dose effect). Our results suggest that estrogen receptor genotyping may be useful in predicting which women would benefit more from tamoxifen...
  22. ncbi request reprint Impact of estrogen receptor expression and other clinicopathologic features on tamoxifen use in ductal carcinoma in situ
    R Barry Hird
    Division of Surgical Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, USA
    Cancer 106:2113-8. 2006
    ..The objective of the current study was to correlate clinicopathologic features of DCIS with ER expression and the impact of this information on tamoxifen counseling...
  23. ncbi request reprint When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer
    H Yamauchi
    Breast Cancer Program, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    J Clin Oncol 19:2334-56. 2001
    ....
  24. pmc The measurement and therapeutic implications of circulating tumour cells in breast cancer
    J B Smerage
    Department of Internal Medicine, Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109, USA
    Br J Cancer 94:8-12. 2006
    ..Future research will focus on the biologic phenotypes of these cells with goals to understand mechanisms of metastasis, to identify novel therapeutic targets, and to monitor response to therapy...
  25. pmc Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients
    J M Rae
    Breast Oncology Program, Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109 0612, USA
    Pharmacogenomics J 9:258-64. 2009
    ..Therefore, patients who may be most likely to benefit from tamoxifen may paradoxically be most likely to discontinue treatment prematurely...
  26. ncbi request reprint Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study
    R A Bok
    University of California at San Francisco, Comprehensive Cancer Center, 94143 0324, USA
    Cancer Res 61:2533-6. 2001
    ..These results support the notion that certain peptide growth factor-mediated, mitogenic pathways are important in HRPC and that their levels can predict outcome...
  27. pmc Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy
    N L Henry
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109, USA
    Br J Cancer 102:294-300. 2010
    ..We hypothesised that inherited variants in candidate genes involved in oestrogen signalling and tamoxifen metabolism might be associated with tamoxifen effects in bone...
  28. pmc Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case-control study
    N L Henry
    Division of Hematology Oncology, Department of Internal Medicine, University of Michigan Medical School, 300 North Ingalls, North Ingalls Building 3A04, Ann Arbor, MI 48109 5419, USA
    Br J Cancer 103:291-6. 2010
    ..Inflammatory mediators are associated with oestrogen signalling and may change with oestrogen depletion. We hypothesised that AIMSS may be associated with changes in circulating inflammatory markers...
  29. ncbi request reprint New prognostic factors for breast cancer recurrence
    C Isaacs
    Breast Cancer Program, Lombardi Cancer Center, Georgetown University, Washington, DC, USA
    Semin Oncol 28:53-67. 2001
    ..This article provides an overview of issues that need to be considered when analyzing studies of prognostic factors, as well as a review of the currently recognized and the newer candidate prognostic factors...
  30. ncbi request reprint Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer
    D F Hayes
    Georgetown University Medical Center, Washington, DC 20007, USA
    Int J Oncol 21:1111-7. 2002
    ..These results demonstrate that it is possible to quantify receptors essential for rationally designed therapy using CECs and that reliance on the immunophenotype of the primary tumor can be misleading...
  31. ncbi request reprint The Role of c-erbB-2 as a predictive factor in breast cancer
    H Yamauchi
    Breast Cancer Program, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, USA
    Breast Cancer 8:171-83. 2001
    ..Importantly, c-erbB-2 status appears critical for selecting patients who should receive trastuzumab. Well-designed prospective randomized clinical trials or formal meta-analysis will help to establish the predictive role of c-erbB-2...
  32. doi request reprint Intravenous interferon administered during liver transplantation is not effective in preventing hepatitis C reinfection
    Mark W Russo
    Transplant Center, Department of Medicine, Carolinas Medical Center, 1000 Blythe Blvd, 3rd Floor Annex Building, Charlotte, NC, 28203, USA
    Dig Dis Sci 58:3010-6. 2013
    ..Post-transplant hepatitis C is a major challenge after liver transplantation (LT). Antiviral therapy is associated with lower efficacy in the post-transplant setting...
  33. ncbi request reprint Changes in surgical management resulting from case review at a breast cancer multidisciplinary tumor board
    Erika A Newman
    Department of Surgery, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109, USA
    Cancer 107:2346-51. 2006
    ..The purpose of the current study was to evaluate the impact of this approach on the surgical management of breast cancer...
  34. ncbi request reprint Assessing the clinical impact of prognostic factors: when is "statistically significant" clinically useful?
    D F Hayes
    Breast Cancer Program, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    Breast Cancer Res Treat 52:305-19. 1998
    ..Perhaps more important, clinical investigators can use TMUGS-Plus to design tumor marker studies that will fulfill criteria for clinical utility, resulting in more rapid acceptance of tumor markers for routine clinical use...
  35. ncbi request reprint Phase II evaluation of thalidomide in patients with metastatic breast cancer
    S M Baidas
    Breast Cancer and Development Therapeutic Programs, Lombardi Cancer Center, Georgetown University Medical Center, Georgetown University, Washington, DC, USA
    J Clin Oncol 18:2710-7. 2000
    ..To determine the efficacy, safety, pharmacokinetics, and effect on serum angiogenic growth factors of two dose levels of thalidomide in patients with metastatic breast cancer...
  36. ncbi request reprint Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody
    C Akewanlop
    The Breast Cancer Program, Lombardi Cancer Center, Georgetown University Medical Center, 3970 Reservoir Road NW, Washington, DC 20007, USA
    Cancer Res 61:4061-5. 2001
    ..Further investigations are needed to determine whether this antibody-induced phagocytosis results in long-term specific T-cell activation against MUC-1...
  37. ncbi request reprint A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors
    J Marshall
    Division of Oncology Hematology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    Ann Oncol 15:1274-83. 2004
    ....
  38. pmc Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by
    Minetta C Liu
    Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3800 Reservoir Road NW, Washington, DC 20007 2198, USA
    Cancer Treat Rev 34:223-30. 2008
    ..A secondary aim was to assess if a higher dose (10 mcg/kg/day) of G-CSF is more efficacious than the conventional dose (5 mcg/kg/day) in this setting...
  39. pmc Monitoring serial changes in circulating human breast cancer cells in murine xenograft models
    Jean Pierre Eliane
    Breast Oncology Program, Comprehensive Cancer Center, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan 48109 0942, USA
    Cancer Res 68:5529-32. 2008
    ..These results establish a new method for studying CTC in mouse models of epithelial cancer, providing the foundation for studies of molecular regulation of CTC in cancer and CTC as biomarker for therapeutic efficacy...
  40. ncbi request reprint Sentinel node biopsy prior to neoadjuvant chemotherapy
    Michael S Sabel
    Breast Oncology Program and Division of Surgical Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA
    Am J Surg 186:102-5. 2003
    ..Sentinel lymph node biopsy prior to induction chemotherapy may address both...
  41. pmc A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients?
    Daniel F Hayes
    J Natl Cancer Inst 100:610-3. 2008
  42. doi request reprint Development and validation of sandwich ELISA microarrays with minimal assay interference
    Rachel M Gonzalez
    Pacific Northwest National Laboratory, 902 Battelle Boulevard, P7 56, Richland, Washington 99354, USA
    J Proteome Res 7:2406-14. 2008
    ..Overall, this research demonstrates the importance of a stringent screening protocol and the value of optimizing the antibody and antigen concentrations when designing chips for ELISA microarrays...
  43. ncbi request reprint Assessing the measure of a new drug: is survival the only thing that matters?
    Daniel J Sargent
    J Clin Oncol 26:1922-3. 2008
  44. doi request reprint Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B
    Michael P Digiovanna
    Yale University School of Medicine, Section of Medical Oncology, 333 Cedar St, Room WWW 217, New Haven, CT 06510, USA
    J Clin Oncol 26:2364-72. 2008
    ....
  45. pmc EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells
    Celina G Kleer
    Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Proc Natl Acad Sci U S A 100:11606-11. 2003
    ..This study provides compelling evidence for a functional link between dysregulated cellular memory, transcriptional repression, and neoplastic transformation...
  46. ncbi request reprint Use of gene-expression profiling to recommend adjuvant chemotherapy for breast cancer
    N Lynn Henry
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109 5843, USA
    Oncology (Williston Park) 21:1301-9; discussion 1311, 1314, 1319. 2007
    ..Large, multinational clinical trials are currently ongoing to evaluate the use of two of the multiparameter assays, although it will be many years before oncologists can apply the results of these trials in the clinic...
  47. ncbi request reprint American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer
    Lyndsay Harris
    Yale Cancer Center, Yale University, New Haven, CT, USA
    J Clin Oncol 25:5287-312. 2007
    ..To update the recommendations for the use of tumor marker tests in the prevention, screening, treatment, and surveillance of breast cancer...
  48. ncbi request reprint Playing the old piano: another tune for endocrine therapy?
    Daniel F Hayes
    J Natl Cancer Inst 95:1565-7. 2003
  49. pmc Drug interactions and pharmacogenomics in the treatment of breast cancer and depression
    N Lynn Henry
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, 300 North Ingalls St, Bldg 3A04, Ann Arbor, MI 48109 5419, USA
    Am J Psychiatry 165:1251-5. 2008
  50. ncbi request reprint Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual
    S Eva Singletary
    Department of Surgical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 106, Houston, TX 77030 4009, USA
    Surg Clin North Am 83:803-19. 2003
    ..By increasing the number of prognostic markers that can give independent information about patient outcome, physicians will be better able to determine optimal treatment approaches for individual patients...
  51. ncbi request reprint Association of angiogenesis and disease outcome in node-positive breast cancer patients treated with adjuvant cyclophosphamide, doxorubicin, and fluorouracil: a Cancer and Leukemia Group B correlative science study from protocols 8541/8869
    Anthony J Guidi
    North Shore Medical Center, Salem, MA, USA
    J Clin Oncol 20:732-42. 2002
    ..However, the utility of this assay in node-positive patients treated with adjuvant cyclophosphamide, doxorubicin, and fluorouracil (CAF) has not been well studied...
  52. ncbi request reprint Cooling off hot flashes
    Vered Stearns
    J Clin Oncol 20:1436-8. 2002
  53. ncbi request reprint Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer
    Vered Stearns
    Breast Cancer Program, Department of Oncology, Lombardi Cancer Center, Georgetown University School of Medicine, Washington, DC, USA
    Ann Surg Oncol 9:235-42. 2002
    ..Sentinel lymphadenectomy (SL) is accepted for axillary evaluation in early breast cancer. We assessed the feasibility and predictive value of SL after neoadjuvant chemotherapy...
  54. ncbi request reprint Approach to menopausal symptoms in women with breast cancer
    Vered Stearns
    The Breast Cancer Program, University of Michigan Comprehensive Cancer Center, 6303 Cancer Center, 1500 E Medical Center Drive, Ann Arbor, MI 48109 0942, USA
    Curr Treat Options Oncol 3:179-90. 2002
    ..Selective serotonin re-uptake inhibitors should be considered as a first-line nonhormonal pharmacologic therapy for women with menopausal symptoms...
  55. ncbi request reprint c-erbB-2 in breast cancer: development of a clinically useful marker
    Daniel F Hayes
    University of Michigan Comprehensive Cancer Center, Department of Medicine, University of Michigan Medical Center, Ann Arbor, MI, USA
    Semin Oncol 29:231-45. 2002
    ..Well-designed, prospective, randomized clinical trials (designed to test the value of c-erbB-2) or formal meta-analyses will help to better establish the predictive role of c-erbB-2 in breast cancer...
  56. ncbi request reprint Revision of the American Joint Committee on Cancer staging system for breast cancer
    S Eva Singletary
    University of Texas M D Anderson Cancer Center and Baylor College of Medicine, Houston, TX, USA
    J Clin Oncol 20:3628-36. 2002
    ..To revise the American Joint Committee on Cancer staging system for breast carcinoma...
  57. ncbi request reprint A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer
    Vered Stearns
    Department of Medicine, Lombardi Cancer Center, Georgetown University School of Medicine, Washington, DC 20007, USA
    Clin Cancer Res 9:124-33. 2003
    ....
  58. ncbi request reprint Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer
    I Craig Henderson
    University of California at San Francisco, San, Francisco, CA 94143, USA
    J Clin Oncol 21:976-83. 2003
    ..This study was designed to determine whether increasing the dose of doxorubicin in or adding paclitaxel to a standard adjuvant chemotherapy regimen for breast cancer patients would prolong time to recurrence and survival...
  59. ncbi request reprint Gene expression profiling of breast cancer: a new tumor marker
    Laura J Van't Veer
    Breast Oncology Program, University of Michigan Health System, 1500 E Medical Center Dr, CCGC 6203, Ann Arbor, MI 48109 0942, USA
    J Clin Oncol 23:1631-5. 2005
  60. ncbi request reprint Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer
    Francisco J Esteva
    University of Texas M D Anderson Cancer Center, and Baylor College of Medicine, Houston, Texas 77030, USA
    J Clin Oncol 21:999-1006. 2003
    ..Bexarotene is a retinoid X receptor-selective retinoid that has preclinical antitumor activity in breast cancer. We evaluated the efficacy and safety of oral bexarotene in the treatment of patients with metastatic breast cancer...
  61. ncbi request reprint Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663
    Mary Ellen Taplin
    University of Massachusetts Memorial Health Center, Department of Oncology, 55 Lake Ave North, Worcester, MA 01655, USA
    J Clin Oncol 21:2673-8. 2003
    ..Bone marrow specimens containing prostate tumor were obtained from men undergoing antiandrogen withdrawal for AR sequence analysis and clinical correlation...
  62. ncbi request reprint Clinicopathologic features of metastasis in nonsentinel lymph nodes of breast carcinoma patients
    Amy C Degnim
    Department of Surgery, University of Michigan, Ann Arbor, Michigan, USA
    Cancer 98:2307-15. 2003
    ....
  63. ncbi request reprint Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine
    Vered Stearns
    The Breast Cancer Program, Department of Medicine, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, USA
    J Natl Cancer Inst 95:1758-64. 2003
    ..In a prospective clinical trial, we tested the effects of coadministration of tamoxifen and the SSRI paroxetine, an inhibitor of CYP2D6, on tamoxifen metabolism...
  64. ncbi request reprint Neoadjuvant docetaxel and capecitabine and the use of thymidine phosphorylase as a predictive biomarker in breast cancer
    Rachel M Layman
    Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109 0848, USA
    Clin Cancer Res 13:4092-7. 2007
    ..We evaluated whether TP protein expression is increased by docetaxel and correlates with pathologic complete response (pCR) in breast cancer patients...
  65. ncbi request reprint Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment
    Silvana Borges
    Department of Medicine, Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, 46202, USA
    Clin Pharmacol Ther 80:61-74. 2006
    ..We conducted a prospective trial in 158 patients with breast cancer who were taking tamoxifen to further understand the effect of CYP2D6 genotype and concomitant medications on endoxifen plasma concentrations...
  66. ncbi request reprint Adjuvant chemotherapy for elderly women with hormone receptor-positive breast cancer: an old(er) problem
    Anne Schott
    J Clin Oncol 22:4660-2. 2004
  67. ncbi request reprint A pilot surrogate end point biomarker trial of perillyl alcohol in breast neoplasia
    Vered Stearns
    Breast Cancer Program, Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, D C, USA
    Clin Cancer Res 10:7583-91. 2004
    ..We report our experience with the natural compound perillyl alcohol (POH) administered in a short-term surrogate end point biomarker (SEB) protocol, using the "window" between diagnostic and definitive surgery...
  68. ncbi request reprint A pilot study to establish a clinical model to perform phase II studies of breast cancer chemopreventive agents in women at high risk with biomarkers as surrogate endpoints for activity
    Vered Stearns
    Breast Cancer Program, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA
    Clin Cancer Res 10:8332-40. 2004
    ..We chose tamoxifen to establish proof of principal with a known effective agent...
  69. ncbi request reprint Combination vinorelbine and capecitabine for metastatic breast cancer using a non-body surface area dosing scheme
    Anne F Schott
    Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, USA
    Cancer Chemother Pharmacol 58:129-35. 2006
    ..A flat dosing scheme of both drugs was used to facilitate development of the oral regimen, and because neither drug's clearance is associated with body surface area (BSA), pharmacokinetic and pharmacogenetic endpoints were explored...
  70. ncbi request reprint CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment
    Yan Jin
    Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    J Natl Cancer Inst 97:30-9. 2005
    ....
  71. ncbi request reprint Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial
    Vered Stearns
    Lombardi Comprehensive Cancer Center at Georgetown University, Washington, DC, USA
    J Clin Oncol 23:6919-30. 2005
    ..A secondary objective was to evaluate quality of life (QOL) parameters...
  72. ncbi request reprint A multicenter randomized clinical trial evaluating interleukin-2 activated hematopoietic stem cell transplantation and post-transplant IL-2 for high risk breast cancer patients
    Claudine Isaacs
    Division of Hematology and Oncology, Lombardi Comprehensive Cancer Center, Washington, DC, 20057, USA
    Breast Cancer Res Treat 93:125-34. 2005
    ..This Phase III randomized multicenter trial compared progression-free (PFS) and overall survival (OS) for autologous peripheral blood stem cell (aPBSC) transplantation with or without immunotherapy in high-risk breast cancer patients...
  73. ncbi request reprint Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer
    Massimo Cristofanilli
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 424, Houston, TX 77030, USA
    J Clin Oncol 23:1420-30. 2005
    ....
  74. ncbi request reprint Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy
    Anne F Schott
    Hematology Oncology Division, Department of Internal Medicine, University of Michigan, MI 48109 0848, USA
    Breast Cancer Res Treat 92:231-8. 2005
    ....
  75. ncbi request reprint Breast cancer
    Robert W Carlson
    Stanford Hospital and Clinics, USA
    J Natl Compr Canc Netw 3:238-89. 2005
  76. ncbi request reprint Circulating tumor cells, disease progression, and survival in metastatic breast cancer
    Massimo Cristofanilli
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    N Engl J Med 351:781-91. 2004
    ..We tested the hypothesis that the level of circulating tumor cells can predict survival in metastatic breast cancer...
  77. ncbi request reprint Heart of darkness: the downside of trastuzumab
    Daniel F Hayes
    J Clin Oncol 24:4056-8. 2006
  78. pmc Recent translational research: circulating tumor cells in breast cancer patients
    Volkmar Muller
    Department of Gynecology, University Medical Center Hamburg Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany
    Breast Cancer Res 8:110. 2006
    ..In this article we briefly summarize recent studies examining the presence of circulating tumor cells in the blood and discuss further clinical applications...
  79. ncbi request reprint Can biology trump anatomy? Do all node-positive patients with breast cancer need chemotherapy?
    N Lynn Henry
    J Clin Oncol 25:2501-3. 2007
  80. ncbi request reprint Tamoxifen: Dr. Jekyll and Mr. Hyde?
    Daniel F Hayes
    J Natl Cancer Inst 96:895-7. 2004
  81. ncbi request reprint Sentinel lymph node biopsy performed after neoadjuvant chemotherapy is accurate in patients with documented node-positive breast cancer at presentation
    Erika A Newman
    Department of Surgery, The University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA
    Ann Surg Oncol 14:2946-52. 2007
    ..We report findings using a novel comprehensive approach to axillary management of node-positive-patients receiving neoadjuvant chemotherapy...
  82. ncbi request reprint Invasive breast cancer
    Robert W Carlson
    National Comprehensive Cancer Network
    J Natl Compr Canc Netw 5:246-312. 2007
  83. ncbi request reprint Quantitative measures of oestrogen receptor and ERBB2 expression
    Daniel F Hayes
    Lancet Oncol 8:184-5. 2007
  84. ncbi request reprint American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
    Antonio C Wolff
    American Society of Clinical Oncology, Alexandria, VA, USA
    J Clin Oncol 25:118-45. 2007
    ..To develop a guideline to improve the accuracy of human epidermal growth factor receptor 2 (HER2) testing in invasive breast cancer and its utility as a predictive marker...
  85. pmc p27(Kip1) and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy
    Peggy L Porter
    Division of Human Biology and Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98109, USA
    J Natl Cancer Inst 98:1723-31. 2006
    ..We studied these markers in a clinical trial setting with patients with breast cancer treated by a uniform drug regimen so that treatment was not associated with variability in outcome...
  86. pmc Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342
    Lyndsay N Harris
    Dana Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115, USA
    Breast Cancer Res 8:R66. 2006
    ..We analyzed data from CALGB 9342, which tested three doses of paclitaxel in women with advanced disease, to determine whether response and outcomes differed according to HER2, hormone receptor, and p53 status...
  87. ncbi request reprint Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer
    G Thomas Budd
    Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Clin Cancer Res 12:6403-9. 2006
    ..In this report, we compared the use of CTCs to radiology for prediction of overall survival...
  88. ncbi request reprint ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer
    Gershon Y Locker
    American Society of Clinical Oncology Tumor Markers Expert Panel, Alexandria, VA 22314, USA
    J Clin Oncol 24:5313-27. 2006
    ..To update the recommendations for the use of tumor marker tests in the prevention, screening, treatment, and surveillance of gastrointestinal cancers...
  89. ncbi request reprint Aromatase inhibitors for the treatment of breast cancer: is tamoxifen of historical interest only?
    Catherine H Van Poznak
    J Natl Cancer Inst 98:1261-3. 2006
  90. ncbi request reprint Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients
    Lynn G Dressler
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, CB 7295, Mason Farm Rd, Chapel Hill, NC 27599 7295, USA
    J Clin Oncol 23:4287-97. 2005
    ....

Research Grants3